This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.Here is a sample of this item:Angiotech loses $7.80-million (U.S.) in Q3 2009-11-09 11:45 ET - News Release Mr. Sharrifah Al-Salem reports ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2009 Angiotech Pharmaceuticals Inc. has released its financial results for the third quarter that ended Sept. 30, 2009.
"We were pleased to observe continued strong sales growth in our proprietary medical products business during the quarter, driven primarily by increasing market adoption of our Quill SRS product line," said Dr. William Hunter, president and chief executive officer. "In addition, our solid early results from our recent commercial launch of the Option Inferior Vena Cava filter and our preparations for a potential 2010 launch of our 5-FU anti-infective product candidates leave us increasingly optimistic about the opportunity to further accelerate growth in our proprietary medical products business in 2010 and beyond."
All amounts are in United States dollars unless otherwise specified.Third-quarter financial highlights: The remainder is available to Stockwatch subscribers.
If you would like to give the Stockwatch system a try,
click here for a free 30 day trial subscription. |
Top
Print this Page